Banque Pictet & Cie’s CRISPR Therapeutics CRSP Stock Holding History

Banque Pictet & Cie’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,805	Closed	-$837K	–	615
2022 Q3	$837K	Sell	12,805 -45	-0.4%	-$3.26K	0.01%	422
2022 Q2	$781	Sell	12,850 -82,578	-87%	-$4.85M	0.01%	468
2022 Q1	$5.99M	Buy	95,428 +626	+0.7%	+$39.3K	0.05%	175
2021 Q4	$7.18M	Buy	94,802 +83,783	+760%	+$7.32M	0.05%	173
2021 Q3	$1.23M	Buy	11,019 +1,238	+13%	+$155K	0.01%	241
2021 Q2	$1.58M	Buy	9,781 +2,994	+44%	+$364K	0.02%	221
2021 Q1	$827K	Buy	6,787 +5,414	+394%	+$817K	0.01%	265
2020 Q4	$210K	Buy	+1,373	New	+$162K	﹤0.01%	315

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Banque Pictet & Cie's CRSP Position: Q4 2022 in Review

Banque Pictet & Cie sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 12,805 shares — an estimated $837K sold.

Banque Pictet & Cie first reported a position in CRSP in Q4 2020 and held it in 8 quarters. The position peaked at $7.18M in Q4 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Banque Pictet & Cie reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
Banque Pictet & Cie sold 12,805 CRISPR Therapeutics shares in Q4 2022, an estimated $837K.
Banque Pictet & Cie first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 8 quarters.
Banque Pictet & Cie's CRISPR Therapeutics position peaked at $7.18M in Q4 2021.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Banque Pictet & Cie's 13F filing for Q4 2022, filed 6 Feb 2023.